| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| D655919-1ml | 1ml | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $412.90 |
| Specifications & Purity | 10mM in DMSO |
|---|---|
| Biochemical and Physiological Mechanisms | DRF-1042 is an orally active derivative of Camptothecin. DRF-1042 acts to inhibit DNA topoisomerase I . DRF-1042 shows good anticancer activity against a panel of human cancer cell lines including multi-agent resistance (MDR) phenotype. |
| Storage Temp | Argon charged,Store at -80°C |
| Shipped In | Ice chest + Ice pads |
| Product Description | DRF-1042 is an orally active derivative of Camptothecin. DRF-1042 acts to inhibit DNA topoisomerase I . DRF-1042 shows good anticancer activity against a panel of human cancer cell lines including multi-agent resistance (MDR) phenotype In Vitro DRF-1042 demonstrates superior lactone stability and good in vitro anticancer activity against a panel of human cancer cell lines including multi-drug resistance (MDR) phenotype. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo In clonogenic assay against murine, canine and human bone marrow cells, DRF-1042 treatment shows less mylosupression that supports the possibility of protracted dose schedule in both experimental and clinical studies. MCE has not independently confirmed the accuracy of these methods. They are for reference only. IC50& Target:DNA topoisomerase I |
| Canonical SMILES | CCC1(C2=C(COC1=O)C(=O)N3C(C4=CC5=CC=CC=C5N=C4C3=C2)OCCO)O |
|---|---|
| Molecular Weight | 408.40 |
Enter Lot Number to search for COA:
